Gilead Sciences, Inc. $GILD Stake Decreased by Hunter Associates Investment Management LLC

Hunter Associates Investment Management LLC lessened its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 13.5% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 14,125 shares of the biopharmaceutical company’s stock after selling 2,200 shares during the period. Hunter Associates Investment Management LLC’s holdings in Gilead Sciences were worth $1,565,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Activest Wealth Management raised its holdings in shares of Gilead Sciences by 2,837.5% during the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 227 shares during the last quarter. GoalVest Advisory LLC raised its holdings in shares of Gilead Sciences by 7,566.7% during the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 227 shares during the last quarter. Harbor Asset Planning Inc. bought a new stake in shares of Gilead Sciences during the second quarter valued at approximately $27,000. Putney Financial Group LLC raised its holdings in shares of Gilead Sciences by 53.4% during the second quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 94 shares during the last quarter. Finally, Colonial Trust Advisors raised its holdings in shares of Gilead Sciences by 304.3% during the first quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 213 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Insiders Place Their Bets

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $118.53, for a total transaction of $3,318,840.00. Following the transaction, the insider directly owned 114,168 shares in the company, valued at approximately $13,532,333.04. The trade was a 19.70% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, September 29th. The stock was sold at an average price of $111.66, for a total transaction of $1,116,600.00. Following the transaction, the chief executive officer owned 591,203 shares in the company, valued at approximately $66,013,726.98. The trade was a 1.66% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 71,500 shares of company stock worth $8,336,040. Corporate insiders own 0.27% of the company’s stock.

Gilead Sciences Trading Up 1.1%

Gilead Sciences stock opened at $119.79 on Monday. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. The firm has a market cap of $148.64 billion, a price-to-earnings ratio of 23.86, a price-to-earnings-growth ratio of 0.81 and a beta of 0.34. Gilead Sciences, Inc. has a 1 year low of $86.08 and a 1 year high of $124.61. The firm’s 50 day moving average price is $115.66 and its two-hundred day moving average price is $111.66.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.16 by $0.31. The firm had revenue of $7.77 billion for the quarter, compared to analyst estimates of $7.42 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The firm’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, research analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th will be given a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 2.6%. The ex-dividend date is Monday, December 15th. Gilead Sciences’s payout ratio is presently 48.99%.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on GILD shares. Weiss Ratings reissued a “buy (b)” rating on shares of Gilead Sciences in a report on Wednesday, October 8th. Daiwa Capital Markets raised Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 target price on the stock in a report on Tuesday, August 19th. Rothschild & Co Redburn boosted their target price on Gilead Sciences from $136.00 to $143.00 and gave the stock a “buy” rating in a report on Friday, September 12th. Cantor Fitzgerald reissued an “overweight” rating and set a $135.00 target price on shares of Gilead Sciences in a report on Friday. Finally, Truist Financial raised Gilead Sciences from a “hold” rating to a “buy” rating and boosted their target price for the stock from $108.00 to $127.00 in a report on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $123.87.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.